11/21
07:15 am
catx
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
High
Report
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
11/15
04:08 pm
catx
Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
High
Report
Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
11/12
04:05 pm
catx
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
Medium
Report
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
10/31
07:00 am
catx
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results
Low
Report
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results
10/29
07:00 am
catx
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
Low
Report
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
10/24
10:09 am
catx
Perspective Therapeutics, Inc. (NYSE: CATX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Low
Report
Perspective Therapeutics, Inc. (NYSE: CATX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
10/24
07:16 am
catx
Perspective Therapeutics, Inc. (NYSE: CATX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $20.00 price target on the stock.
Low
Report
Perspective Therapeutics, Inc. (NYSE: CATX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $20.00 price target on the stock.
10/23
07:00 am
catx
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
Medium
Report
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
10/16
07:00 am
catx
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
Medium
Report
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
10/11
01:49 pm
catx
Perspective Therapeutics, Inc. (NYSE: CATX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $22.00 price target on the stock.
Medium
Report
Perspective Therapeutics, Inc. (NYSE: CATX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $22.00 price target on the stock.
10/11
08:30 am
catx
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
Low
Report
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
10/10
05:14 pm
catx
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
Medium
Report
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
10/7
07:00 am
catx
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
Low
Report
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
10/2
05:58 am
catx
Perspective Therapeutics, Inc. (NYSE: CATX) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Low
Report
Perspective Therapeutics, Inc. (NYSE: CATX) was upgraded by analysts at Wedbush to a "strong-buy" rating.
10/1
08:01 am
catx
Perspective Therapeutics, Inc. (NYSE: CATX) is now covered by analysts at Wedbush. They set an "outperform" rating and a $25.00 price target on the stock.
Medium
Report
Perspective Therapeutics, Inc. (NYSE: CATX) is now covered by analysts at Wedbush. They set an "outperform" rating and a $25.00 price target on the stock.
9/30
07:00 am
catx
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
Medium
Report
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
9/25
08:08 am
catx
Perspective Therapeutics, Inc. (NYSE: CATX) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $21.00 price target on the stock.
Medium
Report
Perspective Therapeutics, Inc. (NYSE: CATX) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $21.00 price target on the stock.
9/10
07:00 am
catx
Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024
Low
Report
Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024
9/9
01:03 pm
catx
Perspective Therapeutics, Inc. (NYSE: CATX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Perspective Therapeutics, Inc. (NYSE: CATX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/5
07:00 am
catx
Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
Low
Report
Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
9/3
10:09 am
catx
Perspective Therapeutics, Inc. (NYSE: CATX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Perspective Therapeutics, Inc. (NYSE: CATX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
8/28
07:00 am
catx
Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
Low
Report
Perspective Therapeutics to Participate in Upcoming Investor Conferences in September